Trexquant Investment LP Acquires 16,248 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Trexquant Investment LP increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 18.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 105,528 shares of the company’s stock after acquiring an additional 16,248 shares during the quarter. Trexquant Investment LP owned about 0.22% of Amphastar Pharmaceuticals worth $3,918,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. TD Private Client Wealth LLC increased its holdings in shares of Amphastar Pharmaceuticals by 22.7% during the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after purchasing an additional 388 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its stake in Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after acquiring an additional 398 shares during the period. Smartleaf Asset Management LLC raised its holdings in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after acquiring an additional 493 shares in the last quarter. KBC Group NV lifted its position in shares of Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after acquiring an additional 650 shares during the period. Finally, Sanctuary Advisors LLC grew its holdings in shares of Amphastar Pharmaceuticals by 8.5% during the 3rd quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock worth $466,000 after purchasing an additional 801 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analyst Ratings Changes

Separately, Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st.

Amphastar Pharmaceuticals Stock Down 2.3 %

Shares of AMPH opened at $26.61 on Friday. The firm has a 50 day simple moving average of $30.24 and a two-hundred day simple moving average of $39.25. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a one year low of $25.89 and a one year high of $53.96. The company has a market cap of $1.27 billion, a P/E ratio of 8.87, a P/E/G ratio of 2.19 and a beta of 0.79.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.